Wolfram Syndrome – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
Wolfram
syndrome, also known by the acronym DIDMOAD, is an inherited condition typically
associated with childhood-onset insulin-dependent diabetes mellitus and
progressive optic atrophy. In addition, many people with Wolfram syndrome also
develop diabetes insipidus and sensorineural hearing loss.
Etiology-
The
two types of Wolfram syndrome (type 1 and type 2) are primarily differentiated
by their genetic cause. Variations
(mutations) in the WFS1 gene are responsible for about 90% of Wolfram syndrome
type 1 cases. This gene encodes wolframin, an essential protein for the
endoplasmic reticulum's proper functioning (the part of a cell involved in
protein production, processing, and transport). Wolframin helps regulate the
amount of calcium in cells, which is essential for many different cellular
functions.
A
specific mutation in the CISD2 gene causes Wolfram syndrome type 2. Although
the exact function of this gene is not known, scientists suspect that it plays a
vital role in the mitochondria (the part of the cell where energy is
produced)—mutations in CISD2 lead to the loss of mitochondria which decreases
the amount of energy available to cells.
Epidemiology-
The
estimated prevalence of Wolfram syndrome type 1 is 1 in 500,000 people
worldwide. Approximately 200 cases have been described in the scientific
literature. Only a few families from Jordan have been found to have Wolfram
syndrome type 2.
The competitive
landscape of Wolfram Syndrome includes country-specific approved and pipeline
therapies. Any asset/product-specific designation or review and Accelerated
Approval are tracked and supplemented with analyst commentary.
KOLs insights of Wolfram
Syndrome across 8 MM market from the center of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Wolfram
Syndrome Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 AMX0035 Amylyx
Pharmaceuticals Phase 1
Comments
Post a Comment